SCHOTT Pharma Achieves Full-Year Revenue and Profitability Targets

SCHOTT Pharma AG & Co. KGaA announced its fiscal 2025 results, reporting a revenue increase to EUR 986.2 million, marking a 5.8% growth at constant currencies. The EBITDA rose significantly by 11.5% to EUR 280.3 million, improving the EBITDA margin to 28.4%.

The Drug Containment Solutions segment led the growth, with revenue rising 11.9% to EUR 548 million, driven by high-value solutions such as sterile ready-to-use cartridges and vials. This segment's EBITDA increased by 34.9%. Conversely, the Drug Delivery Systems segment experienced a slight revenue decline due to decreased demand for polymer syringes.

Despite geopolitical uncertainties, CFO Reinhard Mayer emphasized the company's strengthened financial foundation and focus on innovation and capacity expansion. SCHOTT Pharma projects a 2-5% revenue growth and an EBITDA margin of approximately 27% for fiscal 2026.